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A Double-Blind TVial of Protriptyline in the TVeatment of Sleep
Apnea Syndrome
Edward J. Stepanski, PhD,* William A. Conway, MD,+ David K. Young, MD,'
Frank J. Zorick, MD,* Robert M. Wittig, MD,* and Thomas Roth, PhD*

Eight male subjects with sleep apnea syndrome were given placebo and protriptyline in a double-blind
crossover design to evaluate the effects of protriptyline on respiration during sleep. Treatment with
protriptyline produced significantly better oxygenation and significantly fewer arousals during sleep,
but sleep staging was unchanged. The decreased number of respiratory events approached
significance and was much greater in six of eight subjects. A rapid eye movement sleep-suppression
explanation of the improvement in oxygenation is not .supported. Alternative explanations of these
findings are discussed. (Henry Ford Hosp MedJ 1988:36:5-8)

O

bstmctive sleep apnea is characterized by episodes of upper
airway obstruction which prevent airflow during sleep.
Hypersomnolence and cardiovascular changes, including precipitous decreases in blood hemoglobin oxygen saturation, elevated PCO,, and marked cardiac arrhythmias, are associated
with chronic sleep apnea syndrome. Despite these abnormalities
in sleep-related respiratory function, most patients with this disorder have normal respiration during wakefulness (1).
Treatments for obstructive sleep apnea are surgery or nasal
continuous positive airway pressure (CPAP). Surgical treatment
consists of tracheostomy and more recently uvulopalatopharyngoplasty (UPPP). Tracheostomy, while completely effective,
is subject to both medical and psychological complications.
UPPP has been shown to be effecrive only in a selected subgroup of patients with sleep apnea syndrome (2,3). Generally,
these procedures are indicated in cases of severe sleep apnea
syndrome. The development of nasal CPAP as a treatment for
apneic episodes is an altemative in patients with moderate to severe apnea but is not well tolerated in all patients, particularly in
those with mild apnea. Other treatment options, particularly for
those patients with mild to moderate apnea, are needed.
ProtriptyUne is a tricyclic antidepressant which has a side effect
profile similar to other tricyclic dmgs, except that protriptyline is
nonsedating. Several studies have suggested that treatment with
protriptyline may improve obstmctive apnea (4-7). The reported
degree of success varies in these studies, as does the experimental
methodology employed. Two uncontrolled studies reported sustained improvements in frequency and duration of apneic episodes
in 57% (8/14) and 44% (4/9) of the patients treated with protriptyline (4,5). Daytime hypersomnolence was also reported to
improve. In both studies, the patients with less severe apnea (as determined by number of events) were more likely to respond than
those with severe apnea.
The only controlled study (6) used a double-blind crossover
design (placebo/dmg) to assess treatment in five male subjects
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with moderate apnea. These authors reported significant improvement in measures of oxygenation which were attributed to
the rapid eye movement (REM) sleep-suppressing effect of protriptyline. Obstmctive apneas in REM sleep are longer and have
greater oxygen desaturation than non-REM sleep apneas, and
thus overall oxygenation values improve when the number of
REM events decreases significantly, even though no change occurs in the total number of events. Another study (7) also suggests that decreased REM sleep is the mechanism which leads to
better oxygenation during the night in patients with apnea. Further, during non-REM sleep, many apneic episodes became
hypopneic episodes which also contributed to less hypoxemia
in these patients.
The present study was undertaken to study under controlled
conditions the effects of treatment with protriptyline in a population of patients having mild to moderate apnea.

Methods
The study included eight male subjects, aged 31 to 54 (mean
44.9 ± 7.8 years), with obstmctive sleep apnea. These subjects
were selected if they complained of daytime sleepiness and had
an apnea index of at least 10. The average sleep onset latency
across naps from the Multiple Sleep Latency Test (MSLT) was
5.3 ± 2.5 minutes. All subjects were obese with ideal body
weight ranging from 124% to 187%. Six subjects had essential
hypertension, and three were diagnosed as having chronic
obstmctive pulmonary disease. Two subjects had more serious
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Table 1
Means and Standard Deviations of Sleep Parameters

Placebo
Mean
SD
Protriptyline
Mean
SD

TST
(min)

SE

%1

%2

%REM

403.3
72.4

83.0
12.4

54.2
20.2

33.8
15.4

10.3
7.2

424.6
42.7

86.7
8.3

57.8
18.1

34.2
15.5

6.9
5.2

LAT2
(min)
20.0*
38.3
26.8
39.7

LAT
REM
(min)
85.6*
43.1
164.5
76.1

WDS
(min)

AAR/
HR-TST

75.8
56.8

72.6t
13.9

60.6
42.6

40.7
13.6

*P < 0.05
tP < 0.01
TST = total sleep time, SE = sleep efficiency, %1 = percent stage 1, %2 = percent stage 2, %REM — percent stage rapid
eye movement, LAT2 = latency to stage 2, LAT REM = latency to stage REM, WDS = wake during sleep, and AAR/HR-TST
- arousal associated with respiration per hour of TST.

problems: one had chronic renal failure and received treatment
with dialysis three times each week, and another had a history of
congestive heart failure. Medications aside from the study drug
were used by five subjects and consisted primarily of diuretics.
Bronchodilators were used by two subjects and antihypertensive
drugs by two others.
The initial evaluation included a physical examination, a sleep
history, clinical polysomnography (CPSG), and a MSLT. Polysomnograms consisted of five channels with standard placements for
continuous monitoring of the central (C3) and occipital (OZ)
EEGs, the horizontal electrooculogram, and the submental electromyogram (8). A V5 ECG lead was used to monitor heart rate. An
additional four channels of respiratory recordings included nasal
and oral airflow, diaphragmatic respiratory effort, and blood oxygen saturation measured by a Hewlett-Packard ear oximeter. Sleep
stages were scored according to standard criteria (8).
A double-blind placebo-controlled crossover design with two
treatment conditions was used. Subjects were randomly assigned to one of the two sequences (placebo first or drug first).
Identical 10 mg capsules of placebo or protriptyline were administered for three weeks. After ten days of each drug treatment,
each subject was interviewed to assess compliance with the protocol and the subjective degree of respon.se. Ifno subjective improvement in symptoms was observed, the dosage was increased
to 20 mg. Half the subjects received increased dosages of protriptyline, and 75% received increased dosages of placebo.
After three weeks of nightiy administration, the outcome evaluation which included a nocturnal CPSG and subjective ratings
of daytime sleepiness was performed. Arterial blood gases were
obtained and ventilatory response to hypercapnia was measured
the following day. Protriptyline blood levels were tested at the
end of each three-week trial to assess compliance with the
respective drug regimens. The second drug trial was initiated
immediately following completion ofthe first trial. The entire
protocol was completed in six weeks for each subject.

Sleep parameters
Most sleep parameters were nearly identical on both drug and
placebo (Table 1). The REM-suppression effect of protriptyline
was evident as REM latency increased significantly (r = 2.69,
P < 0.05). Stage REM as a percentage of total sleep time decreased from 10.3 to 6.9. Latency to stage 2 sleep was significantly longer (t = 2.69; P < 0.05) with protriptyline as
compared to placebo. Sleep fragmentation, measured by the
number of arousals associated with respiration per hour of sleep,
showed a significant improvement (t = 3.77, P < 0.01) from a
mean of 72.6 to 40.7 with administration of protriptyline. This
improvement was not reflected in percentage stage 1 sleep,
which remained unchanged for the group as a whole.
Respiratory parameters
Oxygenation during sleep was significantly improved as
measured by the number of minutes below 85% saturation (t =
2.72, P < 0.05) (Table 2). Frequency of apneic episodes decreased from 44.4 events per hour of sleep with placebo to 36.7
events with protriptyline, but this difference was not significant.
The number of apneic episodes in REM or in non-REM sleep
did not change significantly. Six subjects had a lower apnea
index (mean reduction = 33%), while the remaining two worsened. Respiratory events (apneic and hypopneic episodes combined) per hour of sleep decreased from 87.3 to 65.7, which
approached significance (t = 2.22, P < 0.06). All subjects had
fewer respiratory events in the protriptyline condition with a
mean reduction of 22% (range 2.5% to 71%).

Results

Pulmonary functions
Waking blood gases revealed that arterial oxygen increased
from 75 to 80 mm Hg with dmg administration, but this change
was not statistically significant (Table 3). Arterial carbon dioxide decreased in five subjects and was identical in two others.
There was a trend toward reduced PaCO, with protriptyline (t =
2.03, P < 0.10).

Analysis
Mean values from each group for each parameter were compared with matched groups / tests. Criterion for significance was
.set at P = 0.05.

Subjective sleepiness
Five subjects rated their daytime sleepiness as improved on
protriptyline as compared to placebo. The remaining subjects
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rated the two conditions equivalently, with two subjects feeling
that neither treatment was helpful.

Table 2
Means and Standard Deviations of Respiratory
and Oximetry Measures

Discussion
The major finding from this study was the improvement in
oxygen saturation during sleep with protriptyline administration. Subjects had significantly fewer EEG arousals associated
with respiratory events. This finding is important as arousals
have been shown to predict daytime sleepiness in patients with
apnea (9,10). Daytime measures of sleepiness (MSLT) were not
obtained, but nocturnal latency to stage 2 increased significantly, and improvement of sleepiness occurred subjectively in
six subjects.
Previous studies have also reported that oxygenation improves in patients with apnea who take protriptyline. In the present study, this effect cannot be attributed to REM-suppression,
as suggested by Brownell et al (6). Our subjects had low levels of
REM in the placebo condition, and this did not decrease significantiy during the protriptyline trial. In fact, the total REM time
decreased by an average of only 11.8 minutes. The stability of
several other measures also argues against REM suppression as
an explanation of these data. For example, the number of apneic
episodes during REM sleep, the average duration of apneic episodes, or the duration of the longest apneic episode should be
significantly decreased if fewer apneic episodes during REM
sleep were responsible for the improved oxygenation.
A possible mechanism through which protriptyline improves
oxygen saturation was suggested by a recent study on upper airway respiratory motor activity (11). Those authors found that
protriptyline enhanced respiratory activity of the hypoglossal
and recurrent laryngeal nerves. Since the hypoglossal nerve innervates the genioglossal muscle, protriptyline acts to maintain
the patency of the oropharyngeal airway. Increased muscle tone
of the airway, particularly in the oropharynx, might lead to a reduction in the degree of obstruction and subsequently in the
number of obstructive events. Smith et al (7) reported that apneic episodes are more likely to become periods of hypopnea
with use of protriptyline. Altematively, increased airway muscle
tone may lead to a reduced number of severe oxygen desaturations in the presence of obstructive apnea by delaying the
obstmction until later in the inspiratory phase. Consequently,
greater residual volume in the lung would cause less rapid

Placebo*

Protriptyline*

44.4
(24.3)
42.9
(30.4)
52.lt
(15.9)
15.5t
(12.3)
37.5
(22.7)

.36.7
(29.2)
29.0
(16.5)
28.4
(14.1)
8.2
(9.9)
50.3
(19.9)

37.3
(26.4)
255.6
(154.9)
22.0
(4.4)
61.1
(21.6)

21.9
(31.8)
235.1
(204.6)
22.2
(5.6)
57.0
(21.0)

Apnea index
Hypopnea index
Episodes < 85% (index)
Minutes < 85% (index)
Low oxygen (oximetry)
Number of apneas
REM sleep
Non-REM sleep
Mean duration
(seconds)
Longest apnea
(seconds)

*Means are the first reported data, standard deviations are in parentheses,
tp < 0.05
tP < 0.02
Note: Index values are per hour of tolal sleep time.

desaturation during an apneic episode. This same phenomenon
has been offered as a hypothesis to explain why many patients
in whom UPPP fails have markedly improved oxygenation
even though their apnea index is unchanged. Surgically widening the airway and increasing airway muscle tone may be similar
in this regard.
Another possibility is that protriptyline may act as a respiratory stimulant. Smith et al (7) found a significant increase in
waking PaO, with protriptyline administration. Our study
showed a statistical trend toward reduced waking PaCO^ with
protriptyline. Further study of this hypothesis with a larger sample size is needed.
While protriptyline does improve apnea, its effects are inconsistent. Based on the present study and prior research, some
subjects show marked improvement while others are unchanged. The task of future research is to predict which patients

Table 3
Individual Values from Pulmonary Function Tests
Subiecl

Placebo

1
2
3
4
5
6
7
8
Mean
SD

62
73
78
71
62
84
76
77
75
7.3
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PdO,
Protriptyline

—
79
74

—
84
sy
78
78
80.3
5.3

Placebo
45
47
35
38
45
4(1
42
39
41.3
4.3

RiCo,
Protriptyline

Placebo

Vc/Co,
Protriptyline

—
41
35

—

2.41
2.79
1.53

3!
34
41
39
36.8
4.1

—

—

3.12
4.4
3.45
2.95
0.97

3.55
4.7
3.18
3.12
0.96

3.02
2.13
2.15
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will benefit from protriptyline therapy in the management of
their sleep apnea syndrome. Also, research of other medications
which may increase upper airway muscle tone and/or act as respiratory stimulants may lead to effective, safe compounds for
use in the obstmctive sleep apnea syndrome.
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